Welcome : Guest

H1N1 VACCINES - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for H1N1 Vaccines in US$ Million. The report provides separate comprehensive analytics for the US, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 33 companies including many key and niche players such as -

Abbott Laboratories
CPL Biologicals Pvt. Ltd.
bioCSL
GlaxoSmithKline Plc
MedImmune, LLC

Click here to request a full list of companies covered in the report...

Code: MCP-6274
Price: $4950
Companies: 33
Pages: 137
Date: March 2015
Market Data Tables: 18
  Status: * New Report



TABLE OF CONTENTS


  H1N1 VACCINES (Complete Report) Pages : 137   | $4950

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Resurgence of the H1N1 Virus.....II-1
A Glimpse of the 2009 H1N1 Pandemic Outbreak, and the Post-Pandemic Phase.....II-1
1$100
   Efforts to Face Potential Pandemics.....II-2
Competitive Scenario.....II-2
1$100
   H1N1 Influenza Vaccines and Manufacturers.....II-31$100
   Key Growth Drivers.....II-4
Consumer Awareness Drives Market Growth in Developed Regions.....II-4
Emerging Economies Offer Strong Potential.....II-4
1$100
   Threat of Antigenic Shift of H1N1 Virus Lingers.....II-5
Key Growth Inhibitors.....II-5
Requirement of Huge Capital and Large-Scale Investments.....II-5
Stringent Regulatory Scenario.....II-5
1$100
   High Competition Lowers Profit Margins.....II-6
Challenges Facing Healthcare Industry in Tackling Pandemics.....II-6
Cumbersome Production Process, New Technologies Come to Rescue.....II-6
Inefficiencies in Vaccine Distribution: A Cause of Concern.....II-6
1$100
   Shorter Lifecycle of Pandemic Influenza.....II-7
Market Trends.....II-7
Antigenic Shift of Virus Unlocks Possibilities for New Seasonal Influenza
  Vaccines.....II-7
Quadrivalent Vaccines – A Whole New Generation of Seasonal Influenza Vaccines.....II-7
1$100
   Innovations in Vaccine Technology to Drive the Effort for a Universal Influenza
  Vaccine.....II-8
Safety Concerns of Influenza Vaccines Abate.....II-8
1$100
   H1N1 Vaccine Sourced from Tobacco Plants.....II-91$100
   Vaccines Market to Witness Robust Increase in Sales Driven by Robust Demand.....II-101$100
   Pneumococcal and Pediatric Multivalent Vaccines Dominate Sales.....II-11
Table 1: Global Vaccines Market by Category (2014): Percentage Breakdown of Value Sales for Adult Booster, Hepatitis, HPV, Influenza, Meningococcal, Pediatric Multivalent, Pneumococcal, Rotavirus, and Shingles (includes corresponding Graph/Chart).....II-11
1$350
   Competitive Scenario.....II-12
Table 2: Global Vaccines Market by Leading Manufacturer (2014): Percentage Market Share Breakdown of Value Sales for Astra Zeneca, GlaxoSmithKline, Merck & Co, Pfizer, Sanofi Pasteur, and Others (includes corresponding Graph/Chart).....II-12
1$350
   Influenza A (H1N1) 2009: The Global Pandemic.....II-13 1$100
   Table 3: Global Death Toll from 2009 A H1N1 (2009-2012) (includes corresponding Graph/Chart).....II-14

Table 4: Mortality Rates of Major Influenza Pandemics Over the Last 100 Years (includes corresponding Graph/Chart).....II-14
1$350
   Economic Impact of H1N1 Pandemic in Retrospect.....II-15
Healthcare & Pharmaceuticals.....II-15
Pork & Pork Products.....II-15
Airlines, Tourism & Hospitality.....II-15
1$100
   Hand Sanitizers.....II-16
H1N1 Influenza Diagnostic Tests.....II-16
2$200
   Table 5: Global Laboratory Rapid Testing by Leading Player (2014): Percentage Market Share Breakdown of Value Sales for Alere, Quidel, Meridian Bioscience, Beckman Coulter/Danaher, OraSure and Others (includes corresponding Graph/Chart).....II-181$350
   Influenza Virus: A Quick Primer.....II-19
Symptoms and Characteristics.....II-19
Types of Influenza.....II-19
Influenza A Virus.....II-19
Influenza A (H1N1) Virus.....II-19
Different Names, in Different Countries.....II-19
1$100
   Symptoms and Risk Factors.....II-20
The Pandemic Life-Cycle.....II-20
1$100
   Seasonal Influenza vis-à-vis H1N1 Flu.....II-21
How H1N1 Is Diagnosed?.....II-21
Prevention and Vaccination Against H1N1.....II-21
Prevention.....II-21
Vaccination.....II-21
1$100
   Vaccine Virus Selection for the 2015-2016 Influenza Season.....II-22
WHO Recommended Virus Strains for Seasonal Influenza Vaccines for Northern
  Hemisphere for 2015-2016.....II-22
1$100
   WHO Recommended Virus Strains for Seasonal Influenza Vaccines for Southern Hemisphere
  for 2015-2016.....II-23
How is H1N1 Vaccine Prepared?.....II-23
Egg-Based Production Process.....II-23
1$100
   Cell Culture-Based Technology.....II-24
Recombinant Technology.....II-24
1$100
   Side Effects of H1N1 Vaccine.....II-25
Primary Targets for Vaccination.....II-25
Adverse Group for Vaccination.....II-25
Treatment for Swine-Flu Infected Individuals.....II-25
1$100
   Anti-Virals for Pandemic (H1N1) 2009 Infection.....II-26
Recommended Dosage of Anti-Virals.....II-26
Rapivab (Peramivir) – The IV Flu Drug.....II-26
1$100
   FDA Approves Rapivab by BioCryst Pharmaceuticals.....II-27
GSK Obtains Marketing Authorization for Quadrivalent Influenza Vaccine in the UK and
  Germany.....II-27
Sanofi Pasteur’s Review Application for Quadrivalent Influenza Vaccine Accepted by
  EU.....II-27
MedImmune Announces FDA Approval of First Quadrivalent Flu Vaccine.....II-27
Novartis Announces FDA Approval for Cell-Culture Derived Vaccine.....II-27
1$100
   GlaxoSmithKline Obtains FDA Approval for FLUARIX® QUADRIVALENT.....II-28
Tianyuan Receives GMP Certification for Influenza and H1N1 Vaccine.....II-28
1$100
   Serum Institute of India to Launch NasoVacS.....II-29
Bharat Biotech to Produce Swine Flu Vaccine in Bulk.....II-29
Vaxart Announces Positive Trials of its H1N1 Tablet Vaccine.....II-29
A*Star and Cytos Biotechnology Collaborate for H1N1 Vaccine.....II-29
VABIOTECH Develops Vaccines for A/H1N1 and A/H5N1 Viruses.....II-29
Focus Diagnostics and 3M Unveil Simplexa™ Test on 3M™ Integrated Cycler.....II-29
1$100
   GSK Acquires GlycoVaxyn AG.....II-30
Baxter to Divest Vero cell Vaccine Technogy and Assets to Nanotherapeutics.....II-30
Novartis to Divest Influenza Vaccines Business to CSL.....II-30
CALIXAR and VirPath Develop Novel Manufacturing Process for Influenza Vaccines.....II-30
bioCSL Restarts Manufacture of Influenza Vaccine.....II-30
Novartis Begins Shipment of Seasonal Influenza Vaccines to US.....II-30
1$100
   bioCSL Obtains Government Contracts for Vaccine Distribution.....II-31
InGen Biosciences Partners with Quidel and Diagnostic Hybrids.....II-31
1$100
   Abbott Laboratories (US).....II-32
CPL Biologicals Pvt. Ltd. (India).....II-32
bioCSL (Australia).....II-32
1$100
   GlaxoSmithKline Plc. (UK).....II-33
MedImmune, LLC. (US).....II-33
1$100
   Novartis AG (Switzerland).....II-34
Sanofi Pasteur, SA (France).....II-34
1$100
   Sinovac Biotech Ltd. (China).....II-35
Zydus Cadila (India).....II-35
2$200
   Table 6: World Recent Past, Current & Future Analysis for H1N1 Vaccines by Geographic Region - US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart).....II-371$350
   Table 7: World Historic Review for H1N1 Vaccines by Geographic Region - US, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart).....II-381$350
   Table 8: World 12-year Analysis for H1N1 Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe, Asia-Pacific, and Rest of World Markets for the Years 2009, 2015 and 2020 (includes corresponding Graph/Chart).....II-391$350
   A. Market Analysis.....III-1
‘Swine Flu’ Strain Returns in the 2013-14 Season.....III-1
1$85
   Major H1N1 Vaccines Available in the US and Canada.....III-2
US FDA-Approved Influenza Vaccines with 2009 H1N1 Virus Strain Indicated for
  2014-2015 Flu Season.....III-2
US FDA-Approved Quadrivalent Vaccines Incorporating H1N1 Strain for Influenza
  Type A and B (2014-15).....III-2
Preparations Authorized by Health Canada for Influenza, including H1N1, in Canada
  (2014-15 season).....III-2
1$85
   Medicare and Medicaid Services for Influenza in the US.....III-3
Table 9: CDC Price List for Pediatric Influenza Vaccines in Basic Package: 2015-2016.....III-3
1$200
   Table 10: CDC Price List for Adult Influenza Vaccines in Basic Package: 2015-2016.....III-4
A Historical Perspective on the H1N1 Pandemic in North America.....III-4
First Case of H1N1 Infection Reported in Mexico.....III-4
Swine Flu Spreads to the United States.....III-4
1$200
   H1N1 Pandemic Linked to Delay in Vaccine Administration.....III-5
Canadian Government’s H1N1 Mass Vaccination Campaign.....III-5
Product Approvals & Launches.....III-5
1$85
   Strategic Corporate Developments.....III-61$85
   Select Key Players.....III-71$85
   B. Market Analytics.....III-8
Table 11: The US Recent Past, Current & Future Analysis for H1N1 Vaccines Analyzed by Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart).....III-8
1$200
   Table 12: The US Historic Review for H1N1 Vaccines Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart).....III-91$200
   A. Market Analysis.....III-10
H3N2 Viruses Predominate in the 2014/15 Season; H1N1 Still in Circulation.....III-10
An Insight into European Influenza Vaccination Scenario.....III-10
Cell-based Vaccine Production Remains Nascent, Egg-based Widely Used.....III-10
1$85
   Major Influenza Vaccines Available in European Union Member Countries.....III-11
Major H1N1 Flu Vaccines Available in Select East European Markets.....III-11
ECDC Proposes New Influenza Vaccination Strategy.....III-11
Immunization of High-Risk Demographics.....III-11
1$85
   Protecting Children, Adolescents, and Young Adults.....III-12
Stemming the Spread of Infection in Public Centers.....III-12
EU Welcomes Quadrivalent LAIVs.....III-12
Safety Concerns of Influenza Vaccines Abate.....III-12
1$85
   Historical Perspective on the H1N1 Pandemic in Europe.....III-13
Product Approvals & Launches.....III-13
1$85
   Strategic Corporate Developments.....III-14
Select Key Players.....III-14
3$255
   B. Market Analytics.....III-17
Table 13: European Recent Past, Current & Future Analysis for H1N1 Vaccines Analyzed by Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart).....III-17
1$200
   Table 14: European Historic Review for H1N1 Vaccines Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart).....III-181$200
   A. Market Analysis.....III-19
2014-15: Deadliest Swine Flu Season in India Since 2009.....III-19
Leading Influenza H1N1 Vaccine Brands Available in Select Asia-Pacific
  Markets.....III-19
1$85
   Historical Perspective on The Outbreak of H1N1 Pandemic In 2009 In Select
  Regions.....III-20
Japan.....III-20
South Korea.....III-20
Taiwan.....III-20
Malaysia.....III-20
1$85
   Philippines.....III-21
New Zealand.....III-21
India.....III-21
China.....III-21
1$85
   Hong Kong.....III-22
Singapore.....III-22
Australia.....III-22
1$85
   Product Approvals & Launches.....III-231$85
   Strategic Corporate Developments.....III-24
Select Key Players.....III-24
2$170
   B. Market Analytics.....III-26
Table 15: Asia-Pacific Recent Past, Current & Future Analysis for H1N1 Vaccines Analyzed by Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart).....III-26
1$200
   Table 16: Asia-Pacific Historic Review for H1N1 Vaccines Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart).....III-271$200
   Market Analysis.....III-28
Table 17: Rest of World Recent Past, Current & Future Analysis for H1N1 Vaccines Analyzed by Annual Sales Figures in US$ Million for the Years 2014 through 2020 (includes corresponding Graph/Chart).....III-28
1$200
   Table 18: Rest of World Historic Review for H1N1 Vaccines Analyzed by Annual Sales Figures in US$ Million for the Years 2009 through 2013 (includes corresponding Graph/Chart).....III-291$200
  
Total Companies Profiled: 33 (including Divisions/Subsidiaries - 36)

Region/Country Players

The United States 13 Japan 2 Europe 8 France 3 The United Kingdom 2 Rest of Europe 3 Asia-Pacific (Excluding Japan) 13
Click here to request a full table of contents and more details on this project.